Crinetics Pharmaceuticals (CRNX) Operating Leases (2019 - 2026)

Crinetics Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $41.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 5.96% year-over-year to $41.3 million; the trailing twelve-month figure through Mar 2026 stood at $41.3 million (down 5.96% YoY), and the FY2025 full-year result was $42.1 million, down 5.65% from the prior year.
• Operating Leases for Q1 2026 stood at $41.3 million, down from $42.1 million in the prior quarter.
• The five-year high for Operating Leases was $49.1 million in Q3 2025, with the low at $1.5 million in Q2 2023.
• Average Operating Leases over 5 years is $30.0 million, with a median of $43.3 million recorded in 2025.
• Year-over-year, Operating Leases sank 43.24% in 2023 and jumped 3050.62% in 2024.
• Tracing CRNX's Operating Leases over 5 years: stood at $2.0 million in 2022, then jumped by 2249.56% to $47.6 million in 2023, then dropped by 6.28% to $44.6 million in 2024, then declined by 5.65% to $42.1 million in 2025, then decreased by 1.74% to $41.3 million in 2026.
• The last three Operating Leases figures came in at $41.3 million (Q1 2026), $42.1 million (Q4 2025), and $49.1 million (Q3 2025), per Business Quant data.

Peer Comparison